Phase 2 Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01550224
Recruitment Status : Completed
First Posted : March 9, 2012
Last Update Posted : May 21, 2018
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Bruno C. Medeiros, Stanford University

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 17, 2014
  Actual Study Completion Date : November 17, 2014